

Studien am Lungenzentrum

Eudara-CT Sponsor	Studienbezeichnung	Phase von bis Status	PI
2007-00283-73 GSK	MAGRIT: MAGE-A3 as Adjuvant Non-Small Cell LunG CanceR ImmunoTherapy	III 2008 2014 beendet	Voshaar Kambartel Yildirim
2008-002144-42 GSK	VEG111128: An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancer	II 2008 2009 beendet	Voshaar Kambartel
2012-0027900-55 GSK	PEARL: PRAME as Adjuvant immunotherapy in Resected Non-Small Cell Lung Cancer	I/II 2012 2014 geschlossen	Kambartel Voshaar
2010-022656-22 Pfizer	ARCHER 1009: A randomized double blind Phase 3 efficacy and safty Study of PF-00299804 (Dacomitinib) versus Erlotinib fort the Treatment of advanced Non-Small Cell Lung Cancer following Progression after, or Intolerance to, at least one prior Chemotherapy	III 2012 09.11.15 geschlossen	Voshaar Kambartel
2012-003622-25 Astra	"Study 64": A Phase II, Double-Blind, Randomised, Placebo-Contralled Study to Assess the Efficacy and Safty of Selumetinib (AZD6244) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIb-IV)	II 2013 geschlossen	Kambartel Voshaar
2011-001161-41 GSK / Novartis	BRF113928: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations	II geschlossen	Kambartel Yildirim
2013-001676-38 Astra	SELECT-1: A Phase III, Double Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safty of Selumetinib in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation positive Locally Advanced or Metastatic NSCLC (Stage IIIb-IV)	III offen	Kambartel Voshaar
DRKS00004897	SevLoT1a: Randomized, multicenter phase III trial to compare anatomical segmentomy plus radical lymphadenectomy versus standard lobectomy plus radical lymphadenectomy in patients with Non Small Cell Lung Cancer (NSCLC) up to 2cm diameter (pT1a pN0 cMO, Stage Ia) concerning overall-survival, quality of life and complications ()	III offen	Krbek Kopeika
D1532R00004	LUMINIST:	IV	Kambartel

	Lung cancer Molecular Insights Non Interventional Study	26.02.2015 offen	Voshaar
2014-003878-16 Pfizer	A Phase 3 Randomised, Double-blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the First Line Treatment of Patients with Advanced Non-Squamous-Non-Small-Cell Lung-Cancer (NSCLC)	III 12/15 offen	Wiegand Eggert
2015-001123-22 AIO- Studien-gmbH	AIO-TRK-0115 PRIMUS: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)	II 28.01.16 offen	Kambartel Voshaar Yildirim